The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Investigative Dermatology

• Publication date

  2010-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/jid.2010.177PMID 20574441PMCID PMC6550481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.

  2016cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010influential reference
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010influential reference
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

  2010cited by this paper
• Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• BRAFE600 in benign and malignant human tumours

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Regulation and Role of Raf-1/B-Raf Heterodimerization

  2006cited by this paper
• Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

  2006cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Paradoxical activation of Raf by a novel Raf inhibitor.

  1999cited by this paper

• Immunohistochemical study of CD117 in various cutaneous melanocytic lesions

  2020cites this paper
• Targeting mitochondria in melanoma: interplay between MAPK signaling pathway and mitochondrial dynamics.

  2020cites this paper
• Mechanisms of Resistance to Targeted B-Raf Therapies

  2013cites this paper
• Eruptive Squamous Cell Carcinomas after Vemurafenib Therapy

  2013cites this paper
• Resistance to RAF inhibitors revisited

  2013cites this paper
• Advances in personalized medicine - medicinal chemistry and pharmacology of vemurafenib and ivacaftor.

  2013cites this paper
• RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

  2012cites this paper
• Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors

  2012cites this paper
• Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

  2012cites this paper
• Mechanisms of resistance to RAF inhibitors in melanoma

  2011cites this paper
• Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?

  2011cites this paper
• BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety

  2011cites this paper
• 5.2 Role of SOX2 and SOX10 during melanocyte differentiation from human induced pluripotent stem cells

  year unknowncites this paper